Systemic radiation therapy with unsealed radionuclides.
Systemic unsealed radiation therapy is achieved when a radioactive substance is administered orally or parenterally and that material is concentrated in an organ or site for sufficient time to deliver a therapeutic dose of radiation. The radioactive material usually emits beta particles. In general, there is intense local radiation of the abnormal tissues, and normal organs, which do not trap the radioactive material, are exposed to a small radiation dose. The most frequent treatments involve radioiodine (131)I for hyperthyroidism and differentiated thyroid cancer. Other applications include treatment of painful skeletal metastases, polycythemia vera, malignant cysts, and neuroendocrine tumors. The treatments are usually well tolerated and not associated with long-term effects, such as cancer or infertility.
McDougall
I R
IR
Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA.
D001168:Arthritis / Q000532:radiotherapy; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D009447:Neuroblastoma / Q000532:radiotherapy; D010235:Paraganglioma / Q000532:radiotherapy; D011086:Polycythemia / Q000532:radiotherapy; D011868:Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D011878:Radiotherapy / Q000379:methods; D011879:Radiotherapy Dosage; D013921:Thrombocytopenia / Q000532:radiotherapy; D013959:Thyroid Diseases / Q000532:radiotherapy*
D011868:Radioisotopes